The Influence of SARS-CoV-2 Variants B.1.1.7 and B.1.617.2 on a Different Clinical Course and Severity of COVID-19 in Children Hospitalized in 2021 Compared With 2020.
Maria Pokorska-ŚpiewakEwa TalarekMałgorzata PawłowskaAnna ManiaBarbara HasiecElżbieta Żwirek-PytkaMagdalena StankiewiczMartyna StaniPaulina Frańczak-ChmuraLeszek SzenbornIzabela ZaleskaJoanna ChruszczEwa Majda-StanisławskaUrszula DryjaKamila GąsiorowskaMagdalena FiglerowiczKatarzyna Mazur-MelewskaKamil FaltinPrzemysław CiechanowskiMichał PeregrymJoanna Łasecka-ZadrożnaJózef RudnickiBarbara SzczepańskaIlona Pałyga-BysieckaEwelina RogowskaDagmara Hudobska-NawrotKatarzyna Domańska-GranekAdam SybilskiIzabela KucharekJustyna FranczakMałgorzata Sobolewska-PilarczykErnest KucharMichał WronowskiMaria ParyżBolesław KalickiKacper ToczyłowskiArtur SulikSławomira NiedźwieckaAnna GorczycaMagdalena MarczyńskaPublished in: The Pediatric infectious disease journal (2023)
Infections with severe acute respiratory syndrome coronavirus 2 variants alpha and delta lead to a more severe course of COVID-19 with more pronounced clinical presentation and higher fatality rates than infection with an original strain. Most of the children requiring hospitalization due to COVID-19 do not have underlying comorbidities.